New Self-Amplifying RNA vaccines show promise in early COVID-19 trial
NCT ID NCT05037097
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 33 times
Summary
This early-stage study tested three new self-amplifying RNA vaccines against COVID-19 in 72 healthy adults, some already vaccinated and some not. The main goal was to check safety and how well the vaccines triggered an immune response. Results help researchers decide which vaccine candidates to study further.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID - 19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arcturus Investigational Site 101
Singapore, 169608, Singapore
-
Arcturus Investigational Site 201
Kansas City, Missouri, 64114, United States
-
Arcturus Investigational Site 202
Wichita, Kansas, 67207, United States
-
Arcturus Investigational Site 301
Diepkloof, Soweto, 1862, South Africa
Conditions
Explore the condition pages connected to this study.